2024
Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer
Ayoade O, Canavan M, De Santis W, Zhan P, Boffa D. Surgical and Endoscopic Management of Clinical T1b Esophageal Cancer. Journal Of Thoracic And Cardiovascular Surgery 2024 PMID: 38925509, DOI: 10.1016/j.jtcvs.2024.06.011.Peer-Reviewed Original ResearchEsophageal cancerTumor attributesEsophagectomy patientsEndoscopic treatmentAccelerated time failure modelsEndoscopic managementTumor size > 1 cmFactors associated with upstagingOccult lymph node metastasisAssociated with improved survivalAssociated with lymphovascular invasionEffect of esophagectomyT1b esophageal cancerTreatment naive patientsNational Cancer DatabaseWell-differentiated tumorsKaplan Meier analysisLymph node metastasisPoor tumor differentiationTime failure modelsNodal upstagingLymphovascular invasionOverall survivalEndoscopic patientsMeier analysisThe National Cancer Database Conforms to the Standardized Framework for Registry and Data Quality
Palis B, Janczewski L, Browner A, Cotler J, Nogueira L, Richardson L, Benard V, Wilson R, Walker N, McCabe R, Boffa D, Nelson H. The National Cancer Database Conforms to the Standardized Framework for Registry and Data Quality. Annals Of Surgical Oncology 2024, 31: 5546-5559. PMID: 38717542, PMCID: PMC11300494, DOI: 10.1245/s10434-024-15393-8.Peer-Reviewed Original ResearchNational Program of Cancer RegistriesCenters for Disease Control and PreventionCancer RegistryNational Cancer InstituteU.S. Cancer StatisticsDisease Control and PreventionControl and PreventionRate of complianceNational Cancer DatabaseRe-abstractedHospital complianceRegistries' abilityStaff credentialingCancer statisticsHospital benchmarkingAssessed timelinessCancer surveillanceCancer casesData submissionInternal consistencyCase identificationEvaluate adherenceRegistryPolicy decision-makingCancer InstituteSalvage lung resection after immunotherapy is feasible and safe
Nemeth A, Canavan M, Zhan P, Udelsman B, Ely S, Wigle D, Martin L, Yang C, Boffa D, Dhanasopon A. Salvage lung resection after immunotherapy is feasible and safe. JTCVS Open 2024, 20: 141-150. PMID: 39296459, PMCID: PMC11405986, DOI: 10.1016/j.xjon.2024.03.018.Peer-Reviewed Original ResearchNon-small cell lung cancerComplete pathologic responseSalvage lung resectionNational Cancer DatabaseLength of stayStages I-IVLung resectionOligo-progressionOverall survivalSalvage surgeryComplete resection (R0Comprehensive multidisciplinary treatment planHigher R0 resection rateCohort study of patientsInitiation of immunotherapyR0 resection rateTreated with immunotherapySalvage treatment optionMortality rateCell lung cancerLow patient morbidityMedian length of stayKaplan-Meier analysisMultidisciplinary treatment planStudy of patientsSurvival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic
Janczewski L, Browner A, Cotler J, Palis B, Chan K, Joung R, Bentrem D, Merkow R, Boffa D, Nelson H. Survival Among Patients With High-Risk Gastrointestinal Cancers During the COVID-19 Pandemic. JAMA Network Open 2024, 7: e240160. PMID: 38441896, PMCID: PMC10915687, DOI: 10.1001/jamanetworkopen.2024.0160.Peer-Reviewed Original ResearchConceptsStage IV diseaseRetrospective cohort studyCohort studyQuality care deliveryIV diseaseOperative mortalityHigh riskPandemic-related stressorsAssociated with increased 1-year mortalityDiagnosis of stage IMultivariate logistic regressionCOVID-19 pandemicCare deliveryNational Cancer DatabaseKaplan-Meier curvesEvaluate 30-dayMain OutcomesFollow-up dataCancer communityPrepandemic levelsLogistic regressionCancer DatabaseCOVID-19COVID-19 infectionMalignant neoplasms
2023
Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Alterations in Cancer Treatment During the First Year of the COVID-19 Pandemic in the US. JAMA Network Open 2023, 6: e2340148. PMID: 37902756, PMCID: PMC10616721, DOI: 10.1001/jamanetworkopen.2023.40148.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer treatmentAcademic hospitalCommunity hospitalMAIN OUTCOMECOVID-19 pandemicProportion of patientsRetrospective cohort studyAvailability of treatmentFirst yearUnderwent surgeryCohort studyMedian ageCancer surgeryMedian timeTreatment of cancerCancer careTreatment modalitiesCancer screeningCancer DatabaseMedian travel distancePatientsHospitalSurgeryCancerAssociation of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival
Zhang D, Xi Y, Boffa D, Liu Y, Nogueira L. Association of Wildfire Exposure While Recovering From Lung Cancer Surgery With Overall Survival. JAMA Oncology 2023, 9: 1214-1220. PMID: 37498574, PMCID: PMC10375383, DOI: 10.1001/jamaoncol.2023.2144.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerOverall survivalWorse overall survivalLung cancerNSCLC surgeryCohort studyHazard ratioSurgical resectionNSCLC resectionLong-term overall survivalNational Cancer DatabaseLung cancer surgeryLymph node involvementCell lung cancerHealth insurance typeHealth hazardsHospital dischargeNode involvementCancer surgeryStudy endTumor sizeCancer DatabaseInsurance typeHigh riskUnexposed individualsAssessment of a collaborative treatment model for trimodal management of esophageal cancer
Udelsman B, Ermer T, Ely S, Canavan M, Zhan P, Boffa D, Blasberg J. Assessment of a collaborative treatment model for trimodal management of esophageal cancer. Journal Of Thoracic Disease 2023, 15: 4668-4680. PMID: 37868899, PMCID: PMC10586936, DOI: 10.21037/jtd-23-346.Peer-Reviewed Original ResearchPathologic complete responseNational Cancer DatabaseGy of radiationEsophageal cancerCollaborative treatmentCollaborative treatment modelMultiagent chemotherapySingle institutionRate of pCRPatient travel burdenR0 resection rateTreatment modelTrimodality therapyTrimodality treatmentNeoadjuvant chemoradiotherapyNeoadjuvant therapyR0 resectionResection rateComplete responseMultivariable analysisTumor characteristicsCancer DatabaseMedian travel distancePatientsCollaborative CohortOverall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery
Udelsman B, Canavan M, Zhan P, Ely S, Park H, Boffa D, Mase V. Overall survival in low-comorbidity patients with stage I non–small cell lung cancer who chose stereotactic body radiotherapy compared to surgery. Journal Of Thoracic And Cardiovascular Surgery 2023, 167: 822-833.e7. PMID: 37500052, DOI: 10.1016/j.jtcvs.2023.07.021.Peer-Reviewed Original ResearchNon-small cell lung cancerStereotactic body radiotherapyStage I non-small cell lung cancerLow-comorbidity patientsCell lung cancerOverall survivalSurgical managementLung cancerSurgical resectionBody radiotherapyClinical stage I non-small cell lung cancerEarly-stage non-small cell lung cancerPropensity score-matched cohortPropensity score-matched patientsPropensity score-matched analysisEarly-stage lung cancerLong-term OSNational Cancer DatabaseProportion of patientsCancer DatabasePatientsSBRT patientsSurgeryCancerMortalityEffect of pandemic-related reductions in cancer care delivery on different US health systems.
Janczewski L, Cotler J, Merkow R, Palis B, Nelson H, Mullett T, Boffa D. Effect of pandemic-related reductions in cancer care delivery on different US health systems. Journal Of Clinical Oncology 2023, 41: e18811-e18811. DOI: 10.1200/jco.2023.41.16_suppl.e18811.Peer-Reviewed Original ResearchNational Cancer DatabaseHospital typeAcademic hospitalUS healthcare systemTreatment modalitiesCommunity hospitalTreatment utilizationCancer treatmentCOVID-19 pandemicCancer care deliveryTypes of malignanciesHealthcare systemDifferent hospital typesEvaluation of cancerChi-squared testUS health systemFirst yearUnderwent surgerySurgical patientsCancer careCancer DatabaseSurgical carePatientsTreatment declineDescriptive univariate statisticsAssociation Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Udelsman B, Nemeth A, Boffa D. Association Between Metastatic Pattern and Prognosis in Stage IV Gastric Cancer: Potential for Stage Classification Reform. Annals Of Surgical Oncology 2023, 30: 4180-4191. PMID: 36869917, DOI: 10.1245/s10434-023-13287-9.Peer-Reviewed Original ResearchConceptsStage IV gastric cancerNonregional lymph nodesMultivariable Cox modelLymph nodesGastric cancerMetastatic patternCox modelStage IV gastric cancer patientsBetter median survivalNational Cancer DatabaseRetrospective cohort studyStage IV patientsKaplan-Meier curvesGastric cancer patientsPropensity score-matched sampleSingle organYears of ageDistant diseaseCohort studyIV patientsMedian survivalMetastatic diseaseMost patientsBetter prognosisSystemic organsASO Visual Abstract: Evaluation of the Impact of the COVID-19 Pandemic on Reliability of Cancer Surveillance Data in the National Cancer Database
Nogueira L, Palis B, Boffa D, Lum S, Yabroff K, Nelson H. ASO Visual Abstract: Evaluation of the Impact of the COVID-19 Pandemic on Reliability of Cancer Surveillance Data in the National Cancer Database. Annals Of Surgical Oncology 2023, 30: 2094-2094. PMCID: PMC9869810, DOI: 10.1245/s10434-022-13022-w.Peer-Reviewed Original Research
2022
Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Johung K, Boffa D. Utilization and Outcomes of Radiation in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100429. PMID: 36483656, PMCID: PMC9722471, DOI: 10.1016/j.jtocrr.2022.100429.Peer-Reviewed Original ResearchStage IV esophageal cancerNational Cancer DatabaseEsophageal cancerCancer DatabaseRadiation doseSurvival advantageMedian total radiation dosePropensity score-matched pairsOutcome of radiationRetrospective cohort studyKaplan-Meier analysisTotal radiation doseAppropriate radiation dosePalliative regimensCohort studyMedian ageRadiation administrationSurvival associationsBetter survivalPatientsLocal controlCancerDosePalliationFurther studiesNonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer
Zhan P, Canavan M, Ermer T, Pichert M, Li A, Maduka R, Kaminski M, Boffa D. Nonregional Lymph Nodes as the Only Metastatic Site in Stage IV Esophageal Cancer. JTO Clinical And Research Reports 2022, 3: 100426. PMID: 36444359, PMCID: PMC9700291, DOI: 10.1016/j.jtocrr.2022.100426.Peer-Reviewed Original ResearchStage IV esophageal cancerNonregional lymph nodesEsophageal cancerSystemic metastasesLymph nodesMultiorgan metastasesOrgan metastasisSuperior survivalAcademic facility typesOnly metastatic siteNational Cancer DatabaseOutcomes of patientsPatients 18 yearsRetrospective cohort studyStage IV diseaseKaplan-Meier analysisSquamous cell carcinomaPropensity-matched sampleNonregional lymphCohort studyMetastatic involvementMetastatic sitesCell carcinomaCancer DatabaseCox modelEvaluating information loss in the National Cancer Database from cases lost to follow‐up
Cotler JH, Nogueira L, McCabe R, Nelson H, Brajcich BC, Boffa DJ, Lum SS, Harris JB, Hawhee V, Mullett TW, Bilimoria KY, Palis BE. Evaluating information loss in the National Cancer Database from cases lost to follow‐up. Journal Of Surgical Oncology 2022, 126: 1123-1132. PMID: 36029288, DOI: 10.1002/jso.26977.Peer-Reviewed Original ResearchConceptsNational Cancer DatabaseCancer casesPediatric casesAdult casesCancer DatabaseRectal cancer casesLung cancer casesMean survival timeBreast cancer casesHazard ratioCancer RegistryYears postdiagnosisSurvival outcomesLymphoma casesSurvival timeLeukemia casesSurvival analysisResource burdenFollowTotalMinimal differencesYearsAnnual increasePostdiagnosisPatientsImmunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Park HS, Goldberg SB, Boffa DJ. Immunotherapy After Chemotherapy and Radiation for Clinical Stage III Lung Cancer. JAMA Network Open 2022, 5: e2224478. PMID: 35925606, PMCID: PMC9353596, DOI: 10.1001/jamanetworkopen.2022.24478.Peer-Reviewed Original ResearchConceptsStage III non-small cell lung cancerNon-small cell lung cancerClinical stage III non-small cell lung cancerUnresectable stage III non-small cell lung cancerPropensity-matched sampleGeneral US populationSurvival advantageCohort studyLung cancerMultivariable Cox proportional hazards modelsUS populationStage III lung cancerMedian age 66 yearsCox proportional hazards modelNational Cancer DatabaseEfficacy of immunotherapyAge 66 yearsProtocol rangesCell lung cancerClinical trial populationsProportional hazards modelTerms of ageImmunotherapy initiationImmunotherapy recipientsImmunotherapy useAssociation Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US
Ermer T, Canavan ME, Maduka RC, Li AX, Salazar MC, Kaminski MF, Pichert MD, Zhan PL, Mase V, Kluger H, Boffa DJ. Association Between Food and Drug Administration Approval and Disparities in Immunotherapy Use Among Patients With Cancer in the US. JAMA Network Open 2022, 5: e2219535. PMID: 35771575, PMCID: PMC9247736, DOI: 10.1001/jamanetworkopen.2022.19535.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerRenal cell carcinomaUse of immunotherapyFDA approvalImmunotherapy useCohort studyClinical trialsNovel therapiesStage IV non-small cell lung cancerMultivariable logistic regression modelingFirst checkpoint inhibitorCheckpoint inhibitor therapyNational Cancer DatabasePatients 20 yearsCell lung cancerSocioeconomic strataTreatment of patientsDrug Administration approvalLife-saving treatmentReceipt of immunotherapyLogistic regression modelingSocioeconomic characteristicsImmunotherapy administrationCheckpoint inhibitorsPatient characteristicsRevisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer
Pichert MD, Canavan ME, Maduka RC, Li AX, Ermer T, Zhan PL, Kaminski M, Udelsman BV, Blasberg JD, Mase VJ, Dhanasopon AP, Boffa DJ. Revisiting Indications for Brain Imaging During the Clinical Staging Evaluation of Lung Cancer. JTO Clinical And Research Reports 2022, 3: 100318. PMID: 35540711, PMCID: PMC9079298, DOI: 10.1016/j.jtocrr.2022.100318.Peer-Reviewed Original ResearchPrevalence of brainBrain metastasesSummary stageBrain imagingN classificationIsolated brain metastasesNode-negative NSCLCRoutine brain imagingStage II NSCLCStage IV NSCLCClinical stage INational Cancer DatabaseEarly-stage NSCLCStage IAStage IIIAStage NSCLCStaging evaluationClinical stageLung cancerCancer DatabaseN stageNSCLCPatientsStage IMetastasisAppendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology.
Salazar MC, Canavan ME, Chilakamarry S, Boffa DJ, Schuster KM. Appendiceal Cancer in the National Cancer Database: Increasing Frequency, Decreasing Age, and Shifting Histology. Journal Of The American College Of Surgeons 2022, 234: 1082-1089. PMID: 35703801, DOI: 10.1097/xcs.0000000000000172.Peer-Reviewed Original ResearchConceptsRight-sided colon cancerNational Cancer DatabaseAppendiceal cancerColon cancerAcute appendicitisNonoperative managementCancer DatabasePatients 49 yearsPatients 18 yearsArea of residenceLogistic regression modelsAppendiceal histologyPatients 40Appendectomy specimensPatient ageCarcinoid tumorsAppendiceal carcinoidsCancer incidenceCancer histologySmall studyAge groupsCancerCarcinoidsLogistic regressionHistologyNonadherence to Multimodality Cancer Treatment Guidelines in the United States
Tchelebi LT, Shen B, Wang M, Potters L, Herman J, Boffa D, Segel JE, Park HS, Zaorsky NG. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States. Advances In Radiation Oncology 2022, 7: 100938. PMID: 35469182, PMCID: PMC9034283, DOI: 10.1016/j.adro.2022.100938.Peer-Reviewed Original ResearchGuideline-concordant treatmentAnal cancerMultimodality treatmentRectal cancerCervical cancerLung cancerAdvanced non-small cell lung cancerNasopharynx cancerNon-small cell lung cancerNonmetastatic anal cancerNational Cancer DatabasePercent of patientsAdvanced cervical cancerCancer treatment guidelinesCell lung cancerMultivariable logistic regressionPrimary tumor siteLow-volume facilitiesTreatment guidelinesComorbid conditionsCancer DatabaseOdds ratioNational guidelinesPatientsConfounding variablesAccess to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups
Salazar MC, Canavan ME, Holaday LW, Billingsley KG, Ross J, Boffa DJ, Gross CP. Access to High-Volume Hospitals for High-Risk Cancer Surgery for Racial and Ethnic Minoritized Groups. JNCI Cancer Spectrum 2022, 6: pkac024. PMID: 35603855, PMCID: PMC8997114, DOI: 10.1093/jncics/pkac024.Peer-Reviewed Original ResearchConceptsHigh-risk cancer surgeryHigh-volume hospitalsCancer surgeryHispanic patientsNational Cancer DatabaseNon-Hispanic patientsNon-black patientsLung resectionBlack patientsCancer DatabaseBetter outcomesPatientsSurgeryHospitalPancreatectomyLow probabilityInequitable accessEsophagectomyProctectomyResection